CPHI: Trends shaping pharma’s pathThis week CPHI 2023 will unite industry leaders, innovators, and start-ups to explore sustainable solutions, cutting-edge technologies, and collaborative partnerships. more ➔
FinancingXlife Sciences AG acquires 20% stake in 4D...In a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an … more ➔
CollaborationSpliceBio has made up a US $216m alliance...SpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease. more ➔
CollaborationAntiverse and GlobalBio Inc. extend collab...Antiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development more ➔
ADCSOTIO Biotech licenses ADCs from Lonza sub...Sotio hsd licenced Synaffix ADC platform for up to US$740m to develop up to three next generation bioconjugates. more ➔
World Health Summit opened in BerlinOn Sunday, the World Health Summit with more than 300 speakers officially kicked off in Berlin. The three day event focuses on climate change and health, pandemic prevention, and digital technologie … more ➔
financingSynerkine Pharma BV secures EUR 12.1m in S...Dutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01. more ➔
imagingAI helps classifying brain tumours during...A method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers re … more ➔
antibodyAgomab Therapeutics NV raises US$100m in S... Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline. more ➔
financingAstronauTx closes £48m Series A financingAlzheimers specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimers diseas more ➔
